

Study Number: C10277

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: Tricresyl Phosphate

CAS Number: 1330-78-5

Date Report Requested: 08/24/2021

Time Report Requested: 10:51:09

Lab: NTP

Study Number:

C10277

Study Gender:

Male

PWG Approval Date:

See web page for date of PWG Approval

Version:

v1.3.0

Stat Version:

v2.6.3A

Study Number: C10277

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: Tricresyl Phosphate

CAS Number: 1330-78-5

Date Report Requested: 08/24/2021

Time Report Requested: 10:51:09

Lab: NTP

Male

	Phase Day	Treatment Groups (mMol/kg)				
		0	0.169	0.338	0.675	1.35
Urea Nitrogen (mg/dL)	SD 4	9.6 ± 0.2 (5)	10.8 ± 0.7 (5)	10.4 ± 0.9 (5)	13.2 ± 1.6 (5)	9.4 ± 0.4 (5)
Percent of Control			112.5	108.3	137.5	97.9
Creatinine (mg/dL)	SD 4	0.27 ± 0.01 (5)	0.27 ± 0.01 (5)	0.27 ± 0.01 (5)	0.27 ± 0.01 (5)	0.27 ± 0.01 (5)
Percent of Control			97.1	99.3	99.3	100.0
Total Protein (g/dL)	SD 4	5.96 ± 0.12 (5)	5.94 ± 0.08 (5)	5.78 ± 0.06 (5)	5.78 ± 0.04 (5)	5.86 ± 0.04 (5)
Percent of Control			99.7	97.0	97.0	98.3
Globulin (g/dL)	SD 4	2.54 ± 0.07 (5) **	2.58 ± 0.04 (5)	2.52 ± 0.04 (5)	2.58 ± 0.02 (5)	2.62 ± 0.04 (5)
Percent of Control			101.6	99.2	101.6	103.1
A/G Ratio	SD 4	1.35 ± 0.01 (5) **	1.30 ± 0.02 (5)	1.29 ± 0.01 (5) *	1.24 ± 0.02 (5) **	1.24 ± 0.02 (5) **
Percent of Control			96.6	96.0	92.1	91.8
Albumin (g/dL)	SD 4	3.42 ± 0.06 (5) **	3.36 ± 0.05 (5)	3.26 ± 0.02 (5) *	3.20 ± 0.04 (5) *	3.24 ± 0.02 (5) *
Percent of Control			98.2	95.3	93.6	94.7
Cholesterol (mg/dL)	SD 4	113.2 ± 5.1 (5) **	125.6 ± 5.7 (5)	114.0 ± 5.6 (5)	135.6 ± 1.6 (5) **	140.6 ± 4.9 (5) **
Percent of Control			111.0	100.7	119.8	124.2
Triglyceride (mg/dL)	SD 4	52.2 ± 1.1 (5)	55.8 ± 6.2 (5)	45.4 ± 2.5 (5)	51.2 ± 4.0 (5)	51.0 ± 3.2 (5)
Percent of Control			106.9	87.0	98.1	97.7
LDL Cholesterol (mg/dL)	SD 4	23.2 ± 1.3 (5) **	22.0 ± 1.2 (5)	22.2 ± 1.0 (5)	23.8 ± 0.9 (5)	26.8 ± 1.0 (5)
Percent of Control			94.8	95.7	102.6	115.5
HDL Cholesterol (mg/dL)	SD 4	52.0 ± 2.2 (5) **	58.4 ± 2.6 (5)	54.2 ± 3.0 (5)	64.8 ± 0.9 (5) **	63.6 ± 1.7 (5) **
Percent of Control			112.3	104.2	124.6	122.3
Alanine Aminotransferase (IU/L)	SD 4	59.6 ± 4.0 (5) **	89.8 ± 28.6 (5)	78.0 ± 7.6 (5) *	83.8 ± 9.6 (5) *	98.0 ± 11.9 (5) **
Percent of Control			150.7	130.9	140.6	164.4

Study Number: C10277

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: Tricresyl Phosphate

CAS Number: 1330-78-5

Date Report Requested: 08/24/2021

Time Report Requested: 10:51:09

Lab: NTP

Male

	Phase Day	Treatment Groups (mMol/kg)				
		0	0.169	0.338	0.675	1.35
Aspartate Aminotransferase (U/L)	SD 4	109.80 ± 5.58 (5)	181.60 ± 76.90 (5)	131.20 ± 11.61 (5)	116.40 ± 10.76 (5)	116.40 ± 18.12 (5)
Percent of Control			165.4	119.5	106.0	106.0
Sorbitol Dehydrogenase (IU/L)	SD 4	15.0 ± 1.5 (5)	30.2 ± 15.7 (5)	21.6 ± 3.4 (5)	22.8 ± 5.8 (5)	25.2 ± 5.7 (5)
Percent of Control			202.0	144.5	152.5	168.3
Bile salt/acids (umol/L)	SD 4	34.9 ± 4.4 (5)	49.7 ± 10.8 (5)	43.4 ± 6.9 (5)	63.2 ± 8.7 (5)	40.6 ± 8.6 (5)
Percent of Control			142.3	124.3	180.8	116.3

Study Number: C10277

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: Tricresyl Phosphate

CAS Number: 1330-78-5

Date Report Requested: 08/24/2021

Time Report Requested: 10:51:09

Lab: NTP

Male

	Phase Day	Treatment Groups
		2.7
Urea Nitrogen (mg/dL)	SD 4	11.0 ± 0.5 (5)
Percent of Control		114.6
Creatinine (mg/dL)	SD 4	0.30 ± 0.01 (5)
Percent of Control		108.8
Total Protein (g/dL)	SD 4	5.96 ± 0.09 (5)
Percent of Control		100.0
Globulin (g/dL)	SD 4	2.82 ± 0.05 (5) **
Percent of Control		111.0
A/G Ratio	SD 4	1.11 ± 0.01 (5) **
Percent of Control		82.6
Albumin (g/dL)	SD 4	3.14 ± 0.04 (5) **
Percent of Control		91.8
Cholesterol (mg/dL)	SD 4	152.8 ± 3.3 (5) **
Percent of Control		135.0
Triglyceride (mg/dL)	SD 4	51.4 ± 7.1 (5)
Percent of Control		98.5
LDL Cholesterol (mg/dL)	SD 4	28.6 ± 0.9 (5) *
Percent of Control		123.3
HDL Cholesterol (mg/dL)	SD 4	65.6 ± 2.6 (5) **
Percent of Control		126.2
Alanine Aminotransferase (IU/L)	SD 4	104.6 ± 14.2 (5) **
Percent of Control		175.5

Study Number: C10277

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: Tricresyl Phospate

CAS Number: 1330-78-5

Date Report Requested: 08/24/2021

Time Report Requested: 10:51:09

Lab: NTP

Male

	Phase Day	Treatment Groups 2.7
Aspartate Aminotransferase (U/L) Percent of Control	SD 4	116.40 ± 17.21 (5) 106.0
Sorbitol Dehydrogenase (IU/L) Percent of Control	SD 4	19.7 ± 6.1 (5) 131.8
Bile salt/acids (umol/L) Percent of Control	SD 4	32.6 ± 6.3 (5) 93.4

Study Number: C10277

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: Tricresyl Phosphate

CAS Number: 1330-78-5

Date Report Requested: 08/24/2021

Time Report Requested: 10:51:09

Lab: NTP

LEGEND

Values given as mean \pm SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100

SD – Study Day

Statistical analysis was performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at $P \leq 0.05$

** Statistically significant at $P \leq 0.01$

**** END OF REPORT ****